Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11
|
作者：
Liu, Ning [1 ]
Yan, Limei [1 ]
Shan, Fengping [2 ]
Wang, Xiaonai [2 ]
Qu, Na [3 ]
Handley, Mike K. [4 ]
Ma, Mingxing [5 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China
[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China
[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA
[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
来源：
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期
关键词：
Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;
D O I：
10.1016/j.tranon.2021.101028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway
    Bai, Xue
    Ma, Yaxin
    Zhang, Guobin
    ONCOLOGY REPORTS, 2015, 33 (06) : 3085 - 3092
  • [2] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [3] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
    Dobbin, Zachary C.
    Landen, Charles N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
  • [4] α2A-Adrenergic Receptor Inhibits the Progression of Cervical Cancer Through Blocking PI3K/AKT/mTOR Pathway
    Wang, Weina
    Guo, Xin
    Dan, Huiwen
    ONCOTARGETS AND THERAPY, 2020, 13 : 10535 - 10546
  • [5] CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway
    Xiao, Huan
    Zhang, Zhi'an
    Wei, Chunqing
    Peng, Dan
    Guo, Yuge
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2023, 44 (01) : 106 - 114
  • [6] MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway
    Su, Wei
    Feng, Baijie
    Hu, Lina
    Guo, Xianzhi
    Yu, Minghua
    BMC CANCER, 2022, 22 (01)
  • [7] MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway
    Wei Su
    Baijie Feng
    Lina Hu
    Xianzhi Guo
    Minghua Yu
    BMC Cancer, 22
  • [8] Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway
    Chenhao Tong
    Yali Wang
    Jiandong Li
    Wenda Cen
    Weiguang Zhang
    Zhiyang Zhu
    Jianhua Yu
    Baochun Lu
    Scientific Reports, 11
  • [9] Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway
    Tong, Chenhao
    Wang, Yali
    Li, Jiandong
    Cen, Wenda
    Zhang, Weiguang
    Zhu, Zhiyang
    Yu, Jianhua
    Lu, Baochun
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [10] PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
    Lisi, Lucia
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2161 - 2163
12345